HOME > TOP STORIES

TOP STORIES

REGULATORY MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets

February 10, 2015
ACADEMIA Keio Researcher to Launch Clinical Trial on Repositioned AD Treatment in April

February 9, 2015
ORGANIZATION PhRMA Sets to Make Direct Plea to Finance Minister to Drop Annual Price Cut Plan

February 6, 2015
REGULATORY NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General

February 6, 2015
BUSINESS Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP

February 5, 2015
REGULATORY MHLW Plans Business Suspension Order for Novartis

February 5, 2015
REGULATORY R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto

February 4, 2015
BUSINESS Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore

February 4, 2015
BUSINESS Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies

February 3, 2015
BUSINESS Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy

February 2, 2015
REGULATORY Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015

January 30, 2015
BUSINESS Chugai Sales Grow 8.8% Thanks to Increasing Actemra Exports

January 29, 2015
BUSINESS PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst

January 28, 2015
BUSINESS Cost of Producing Antibody Drugs Remains High Despite Improvement in Culture Efficiency: Kyowa Kirin

January 27, 2015
REGULATORY Japan-Version Compassionate Use May Cover Drugs with No Approval Globally

January 26, 2015
REGULATORY Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28

January 23, 2015
BUSINESS Open Tenders Good Example of Early Price Settlements: Qol Exec

January 22, 2015
ORGANIZATION Some LDP Members Keen to Tackle Kampo NHI Price Problem

January 21, 2015
REGULATORY R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017

January 21, 2015
REGULATORY R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways

January 20, 2015

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…